[Key Financial Data](index=2&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) [Core Financial Indicators](index=2&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In Q3 2022, operating revenue grew by **55.78%**, but net profit declined, with year-to-date net profit down **18.27%** despite a **4.06%** revenue increase, indicating profitability challenges Key Financial Data for Q3 2022 and Year-to-Date | Indicator | Current Period (Q3 2022) (CNY) | YoY Change (Current Period) | YTD (Q3 2022) (CNY) | YoY Change (YTD) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,063,676,865.47 | 55.78% | 2,401,523,534.17 | 4.06% | | Net Profit Attributable to Shareholders | 22,782,631.86 | -3.99% | 82,996,425.93 | -18.27% | | Net Cash Flow from Operating Activities | - | - | 54,425,322.06 | 17.95% | | Basic Earnings Per Share | 0.09 CNY/share | -18.18% | 0.33 CNY/share | -17.50% | | Total Assets (Period-End) | 1,830,833,597.44 | 11.80% (vs. Prior Year-End) | 1,830,833,597.44 | 11.80% (vs. Prior Year-End) | | Shareholders' Equity Attributable to Parent (Period-End) | 841,393,967.60 | 10.94% (vs. Prior Year-End) | 841,393,967.60 | 10.94% (vs. Prior Year-End) | [Non-Recurring Gains and Losses](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Year-to-date, non-recurring gains and losses totaled **8.42 million CNY**, primarily from **12.10 million CNY** in government subsidies and tax incentives, effectively supplementing current profit Non-Recurring Gains and Losses Items for YTD 2022 | Item | Amount (CNY) | Description | | :--- | :--- | :--- | | Government subsidies included in current profit/loss | 12,098,258.94 | Receipt of government subsidies and tax incentives | | Non-current asset disposal gains/losses | -7,258.83 | Loss from disposal of fixed assets | | **Total** | **8,419,934.40** | -- | [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) [Shareholding Structure](index=3&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period end, the company had **16,350** common shareholders, with the top two holding **46.25%** and **16.15%** respectively, indicating a relatively concentrated equity structure - As of the reporting period end, the company's total number of common shareholders was **16,350**[9](index=9&type=chunk) Top Two Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares | | :--- | :--- | :--- | :--- | | Shaanxi Pharmaceutical Holdings Group Co., Ltd. | State-owned Legal Person | 46.25% | 116,550,000.00 | | Hong Kong Yuanshi International Co., Ltd. | Overseas Legal Person | 16.15% | 40,704,440.00 | - Some of the top ten shareholders have related party relationships: Shanghai Jiangnan Architectural Planning Consulting Co., Ltd. is a wholly-owned subsidiary of Shanghai Jiangnan Architectural Design Institute (Group) Co., Ltd., and Jin Jun is a director of the latter[10](index=10&type=chunk) [Other Significant Matters](index=4&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Progress on Major Projects](index=4&type=section&id=1%E3%80%81%E7%8E%AF%E7%90%83%E5%8D%B0%E5%8A%A1%E6%89%A9%E4%BA%A7%E6%9A%A8%E7%BB%BF%E8%89%B2%E5%8C%85%E8%A3%85%E6%99%BA%E8%83%BD%E5%88%B6%E9%80%A0%E5%B7%A5%E4%B8%9A%E5%9B%AD%E9%A1%B9%E7%9B%AE) The "Global Printing Expansion and Green Packaging Smart Manufacturing Industrial Park Project" is progressing, with an engineering general contract signed, aiming to expand pharmaceutical packaging capacity and establish an R&D center - The company's "Green Packaging Smart Manufacturing Industrial Park Project" in Xixian New Area Airport New City is proceeding normally, encompassing primary and secondary pharmaceutical packaging production centers and a technology R&D center[10](index=10&type=chunk) - During the reporting period, the company's wholly-owned subsidiary Lingfeng Global signed a "Construction Project General Contract" with China Construction Fourth Engineering Division Corp., Ltd., moving the project into a substantive construction phase[10](index=10&type=chunk) [Refinancing Plan](index=4&type=section&id=2%E3%80%81%E9%9D%9E%E5%85%AC%E5%BC%80%E5%8F%91%E8%A1%8C%20A%20%E8%82%A1%E8%82%A1%E7%A5%A8%E4%BA%8B%E9%A1%B9) The non-public issuance of A-shares, approved by the CSRC, plans to issue up to **68,040,000** shares to no more than 35 specific investors, and is currently being advanced for opportunistic issuance - The company's application for non-public issuance of A-shares was approved by the China Securities Regulatory Commission (CSRC) on March 2, 2022 (CSRC Permit [2022] No. 397)[11](index=11&type=chunk) - The company plans to issue no more than **68,040,000** shares and is currently proceeding with the issuance, which will be executed opportunistically within the validity period[11](index=11&type=chunk) [Major Shareholder Reduction Plan](index=5&type=section&id=4%E3%80%815%25%E4%BB%A5%E4%B8%8A%E8%82%A1%E4%B8%9C%E5%87%8F%E6%8C%81%E4%BA%8B%E9%A1%B9) Major shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to **6%** of total share capital within six months, potentially impacting share price - Shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its holdings by no more than **15,120,000** company shares, representing **6%** of the company's total share capital[14](index=14&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) [Consolidated Balance Sheet Analysis](index=6&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of Sep 30, 2022, total assets were **1.83 billion CNY**, up **11.80%** from year-start, with liabilities at **894.92 million CNY**; significant increases in prepayments, short-term borrowings, and contract liabilities reflect business expansion and increased advance receipts Balance Sheet Key Item Changes (Sep 30, 2022 vs Jan 1, 2022) | Item | Period-End Balance (CNY) | Year-Start Balance (CNY) | Change | | :--- | :--- | :--- | :--- | | **Total Assets** | **1,830,833,597.44** | **1,637,617,535.07** | **+11.80%** | | Prepayments | 436,814,008.85 | 154,366,910.40 | +182.98% | | **Total Liabilities** | **894,921,659.65** | **793,088,893.48** | **+12.84%** | | Short-term Borrowings | 339,833,395.93 | 232,118,875.75 | +46.40% | | Contract Liabilities | 114,208,148.15 | 10,957,078.63 | +942.31% | | **Total Equity Attributable to Parent Company Owners** | **841,393,967.60** | **758,397,541.67** | **+10.94%** | [Consolidated Income Statement Analysis](index=8&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E5%88%A9%E6%B6%A6%E8%A1%A8) In Q1-Q3 2022, operating revenue reached **2.40 billion CNY**, up **4.06%**, but higher cost growth and a sharp decline in investment income led to a **23.09%** drop in operating profit and an **18.27%** decline in net profit, indicating profitability pressure Income Statement Key Item Changes (Q1-Q3 2022 vs Q1-Q3 2021) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 2,401,523,534.17 | 2,307,918,790.20 | +4.06% | | Operating Cost | 2,171,219,418.50 | 2,061,101,044.24 | +5.34% | | Investment Income | 2,581,851.90 | 13,990,821.86 | -81.55% | | Operating Profit | 104,724,011.82 | 136,155,442.35 | -23.09% | | Net Profit Attributable to Parent Company Shareholders | 82,996,425.93 | 101,549,331.34 | -18.27% | [Consolidated Cash Flow Statement Analysis](index=9&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In Q1-Q3 2022, net cash flow from operating activities was **54.43 million CNY**, up **17.95%**, while investment and financing activities resulted in net outflows, leading to a decrease in cash and cash equivalents Cash Flow Statement Key Items (Q1-Q3 2022) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 54,425,322.06 | 46,144,103.80 | | Net Cash Flow from Investing Activities | -50,296,585.80 | -97,479,777.32 | | Net Cash Flow from Financing Activities | -53,296,378.38 | 16,322,547.83 | | Net Increase in Cash and Cash Equivalents | -49,167,642.12 | -35,013,125.69 |

Financial Performance - The company reported a revenue of CNY 1,337,846,668.70 for the first half of 2022, a decrease of 17.68% compared to CNY 1,625,130,768.07 in the same period last year[20]. - Net profit attributable to shareholders was CNY 60,213,794.07, down 22.62% from CNY 77,818,940.60 year-on-year[20]. - Basic and diluted earnings per share decreased to CNY 0.24, down 22.58% from CNY 0.31 in the same period last year[20]. - The company's operating revenue for the reporting period was ¥1,337,846,668.70, a decrease of 17.68% compared to ¥1,625,130,768.07 in the same period last year[67]. - The company's operating costs decreased by 18.68% to ¥1,180,903,132.68 from ¥1,452,150,021.94 year-on-year[67]. - The net profit for the first half of 2022 was CNY 68,920,718.90, a decrease from CNY 92,101,232.11 in the first half of 2021, which is a decline of around 25.14%[185]. - The total profit for the first half of 2022 was CNY 73,924,199.72, down from CNY 104,923,398.90 in the first half of 2021, reflecting a decline of about 29.54%[184]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to CNY 35,540,255.46, a rise of 3,578.23% compared to CNY 966,233.16 in the previous year[20]. - The company reported a net increase in cash and cash equivalents of ¥7,450,861.59, compared to a decrease of ¥31,616,747.42 in the previous year[67]. - Cash and cash equivalents at the end of the reporting period were ¥305,141,629.07, a slight decrease of 0.85% from ¥299,361,975.03[72]. - The total cash inflow from financing activities was CNY 361,549,956.32, compared to CNY 264,323,567.81 in the previous year, reflecting a 37% increase in financing efforts[190]. - The total cash and cash equivalents at the end of the period increased to CNY 283,581,140.29 from CNY 260,444,662.53, marking a positive change in liquidity[190]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,750,462,739.97, reflecting a growth of 6.89% from CNY 1,637,617,535.07 at the end of the previous year[20]. - Current liabilities rose to CNY 802,670,111.71, up from CNY 741,040,523.41, indicating an increase of 8.5%[179]. - Non-current liabilities decreased to CNY 34,343,267.77 from CNY 52,048,370.07, a reduction of 34.0%[179]. - The total balance of restricted assets at the end of the reporting period was ¥22,145,241.14, down from ¥26,532,891.77 at the end of the previous year[4]. Research and Development - Research and development investment increased by 10.12% to ¥28,385,361.25 from ¥25,777,866.63 year-on-year[67]. - The company is increasing its research and development investments to keep pace with technological advancements in automation and artificial intelligence[96]. - The company has obtained 18 new patents and 3 software copyrights during the reporting period, with a total of 161 intellectual property rights, maintaining its leading position in the industry[47]. Market Position and Strategy - The company ranks 15th in the "2022 Top 100 Printing and Packaging Enterprises in China" list, indicating its leading position in the pharmaceutical packaging sector[36]. - The company is focusing on expanding its pharmaceutical packaging business, particularly in the chemical drug market, ensuring the achievement of operational goals[31]. - The company aims to maintain stable growth in the pharmaceutical packaging sector while exploring new business models in digital marketing and supply chain management[36]. - The company is actively developing high-end packaging for fast-moving consumer goods, health products, and cosmetics, targeting well-known domestic and international clients[37]. Environmental and Social Responsibility - The company emphasizes safety and environmental protection, implementing strict safety management and training programs[34]. - The company has established two sets of organic waste gas treatment facilities, which are operating well without any abnormalities during the reporting period[111]. - The company is committed to social responsibility, providing educational subsidies to two employees to enhance their skills[117]. - The company has implemented measures to reduce carbon emissions, although specific results were not detailed in the report[116]. Corporate Governance - The company has maintained stable governance with no changes in its board or management during the reporting period[106]. - The controlling shareholder, Shaanxi Medical Holdings Group, holds a 65% stake in the company and has made commitments to avoid related party transactions[121]. - The company has committed to ensuring that any necessary transactions with related parties will adhere to market principles and fair pricing[121]. Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[183]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[195].

西安环球印务股份有限公司 2022 年第一季度报告 证券代码：002799 证券简称：环球印务 公告编号：2022-022 西安环球印务股份有限公司 2022年第一季度报告 本公司及全体董事保证本公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务 信息的真实、准确、完整。 3、第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -980.77 | 处置固定资产损失 | | 计入当期损益的政府补助（与公司正常经营业务密切相关， 符合国家政策规定、按照一定标准定额或定量持续享受的政 府补助除外） ...

Financial Performance - The company's operating revenue for 2021 was approximately ¥2.94 billion, representing a 56.57% increase compared to ¥1.88 billion in 2020[19]. - The net profit attributable to shareholders for 2021 was approximately ¥106.36 million, a 5.00% increase from ¥101.29 million in 2020[19]. - The net cash flow from operating activities improved significantly to approximately ¥117.61 million, a 364.47% increase from a negative cash flow of ¥44.47 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥1.64 billion, reflecting a 9.21% increase from ¥1.50 billion at the end of 2020[19]. - The net assets attributable to shareholders increased by 13.26% to approximately ¥758.40 million at the end of 2021, up from ¥669.61 million at the end of 2020[19]. - The basic earnings per share for 2021 was ¥0.42, a 5.00% increase from ¥0.40 in 2020[19]. - The weighted average return on equity for 2021 was 14.89%, a slight decrease of 0.74% from 15.63% in 2020[19]. - The company reported a decrease of 3.79% in net profit after deducting non-recurring gains and losses, totaling approximately ¥89.11 million in 2021 compared to ¥92.62 million in 2020[19]. Market Position and Growth - The company ranked 20th in the "2021 Top 100 Printing and Packaging Enterprises in China" list, highlighting its leading position in the pharmaceutical packaging sector[36]. - The company maintains stable growth in the pharmaceutical packaging sector, with established partnerships with major pharmaceutical companies including Bayer, Johnson & Johnson, and Novartis[36]. - The company aims to expand its market presence beyond China, targeting regions such as Hong Kong, Japan, and Southeast Asia[36]. - The pharmaceutical packaging industry is expected to maintain stable profit levels, despite fluctuations in raw material prices impacting overall profitability[31]. - The pharmaceutical packaging market is projected to grow from $111 billion in 2021 to $118 billion by 2026, with a compound annual growth rate of 8.24%[134]. Research and Development - The company has developed a blockchain-based traceability management system for pharmaceuticals and consumer goods, integrating modern technologies like 5G and IoT[41]. - The company is focusing on enhancing product quality and processing efficiency through innovations in drug packaging technology[88]. - The company's R&D investment amounted to ¥82,223,343.90 in 2021, representing a 46.77% increase from ¥56,021,167.75 in 2020[92]. - R&D personnel increased to 215 in 2021, up 17.49% from 183 in 2020, with R&D personnel accounting for 19.37% of the total workforce[92]. - The company is committed to increasing R&D investment to keep pace with technological advancements and ensure continuous improvement in products and services[150]. Strategic Initiatives - The company has initiated a green packaging intelligent manufacturing project, investing nearly CNY 100 million in land purchase and preliminary design[68]. - The company is entering the live e-commerce sector and exploring digital marketing in the metaverse, focusing on virtual digital image creation and virtual idol IP operations[139]. - The company plans to leverage capital market financing to support capacity expansion and intelligent upgrades in Xi'an and Tianjin, enhancing its product line and service efficiency[138]. - The company aims to implement a C2M supply chain model, providing collaborative management services from raw materials to consumers[144]. Corporate Governance - The company has established a robust corporate governance structure, holding 9 board meetings and 8 supervisory meetings to ensure compliance with legal requirements[164][165]. - The company emphasizes transparency and timely information disclosure to protect shareholders' rights and enhance corporate governance[168]. - The company maintains independence from its controlling shareholder in business operations, personnel, assets, and finances, ensuring no non-operating fund transfers occurred during the reporting period[163]. - The company has a fully independent human resources department, managing personnel matters without interference from shareholders[173]. Risks and Challenges - The company has indicated potential risks in its future development outlook, which investors should be aware of[4]. - The company faces risks from national policy changes affecting the pharmaceutical and consumer goods sectors, and it will adapt its strategies accordingly[145]. - The company is facing risks from fluctuations in raw material prices, particularly in industrial packaging paper, which could impact sales revenue if costs rise significantly[153]. - The company has implemented strict sales collection policies to reduce the proportion of accounts receivable to operating income, thereby improving cash flow[154].

Financial Performance - The company's revenue for Q3 2021 reached ¥682,788,022.13, representing a 59.18% increase compared to the same period last year[4] - The net profit attributable to shareholders was ¥23,730,390.74, a decrease of 1.85% year-on-year, while the net profit excluding non-recurring items was ¥20,881,278.03, up 1.43%[4] - The company's operating income increased to CNY 2,639,408,582.41, representing an 88.74% growth compared to the previous period[11] - Total operating revenue for Q3 2021 reached ¥2,307,918,790.20, a significant increase of 80.5% compared to ¥1,275,526,633.30 in Q3 2020[25] - Operating profit for Q3 2021 was ¥136,155,442.35, up 40.3% from ¥97,069,099.80 in the same period last year[26] - Net profit attributable to the parent company for Q3 2021 was ¥101,549,331.34, representing a 54.9% increase from ¥65,570,467.64 in Q3 2020[26] - The total comprehensive income for the period reached ¥118,749,758.29, compared to ¥81,710,268.93 in the previous period, reflecting a significant increase[27] - The net profit attributable to the parent company was ¥101,549,331.34, up from ¥65,570,467.64, indicating a growth of approximately 54.9%[27] - Basic and diluted earnings per share both stood at ¥0.40, compared to ¥0.26 in the previous period, representing a 53.8% increase[27] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,726,182,157.23, reflecting a 15.12% increase from the end of the previous year[5] - Total assets as of September 30, 2021, amounted to ¥1,726,182,157.23, compared to ¥1,499,501,682.56 at the end of 2020, reflecting a growth of 15.1%[23] - Total liabilities increased to ¥889,053,567.44 as of September 30, 2021, from ¥752,787,414.95 at the end of 2020, marking a rise of 18.1%[23] - Current assets totaled ¥1,043,388,343.18, up 17.7% from ¥886,093,307.99 at the end of 2020[22] - Owner's equity totaled CNY 746,714,267.61, with total equity attributable to shareholders at CNY 669,611,645.99[35] Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥46,144,103.80[4] - Cash inflows from operating activities totaled ¥2,650,294,570.86, a substantial rise from ¥1,414,790,818.85, marking an increase of about 87.2%[30] - The net cash flow from operating activities was ¥46,144,103.80, recovering from a negative cash flow of ¥111,360,678.46 in the previous period[30] - Cash received from tax refunds rose by 47.94% to CNY 526,500.00, primarily due to income tax refunds received during the reporting period[11] - Cash outflows for investing activities amounted to ¥107,684,489.87, compared to ¥19,801,637.55 in the previous period, indicating increased investment activity[31] - The ending balance of cash and cash equivalents was ¥257,048,284.26, compared to ¥238,200,718.04 at the end of the previous period, showing a slight increase[31] Investment and Expenses - Research and development expenses rose by 74.21% to ¥41,602,594.76, indicating increased investment in innovation[10] - Research and development expenses for Q3 2021 were ¥41,602,594.76, significantly higher than ¥23,880,225.70 in Q3 2020, indicating a focus on innovation[26] - The investment income for the period was ¥13,990,821.86, a 144.18% increase, reflecting improved performance from equity investments[10] - Investment income received reached CNY 9,019,519.78, attributed to dividend distributions from subsidiaries[11] - The company has increased cash payments for fixed assets and equipment by 619.04% to CNY 88,333,410.36, mainly for land acquisition and key production equipment[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,775, with no preferred shareholders[13] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds a 46.25% stake in the company[13] Future Plans - The company is expanding its production capacity with a new green packaging smart manufacturing industrial park project in Xi'an, signed on March 26, 2021[16] - A non-public offering of A-shares is planned, with a maximum issuance of 68,040,000 shares, representing up to 27% of the total share capital before the issuance[17] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24] Other Information - The company reported a significant increase in accounts receivable by 30.70% to ¥375,325,014.53, attributed to higher revenue[10] - The company experienced a 1410.11% increase in contract liabilities, reaching ¥36,478,596.37, due to increased customer prepayments[10] - Cash flow from financing activities decreased by 48.23% to CNY 103,550,000.00, primarily due to reduced borrowings from Shaanxi Pharmaceutical Group[11] - The report for the third quarter was not audited[38]

Financial Performance - The company achieved operating revenue of CNY 1,625,130,768.07, representing a year-on-year increase of 91.96%[20] - The net profit attributable to shareholders reached CNY 77,818,940.60, up 88.00% compared to the same period last year[20] - The net profit after deducting non-recurring gains and losses was CNY 71,369,960.40, reflecting a growth of 91.80% year-on-year[20] - The basic earnings per share increased to CNY 0.31, a rise of 93.75% from CNY 0.16 in the previous year[20] - The company's revenue for the reporting period reached ¥1,625,130,768.07, a 91.96% increase compared to ¥846,595,674.22 in the previous year, primarily driven by the growth in the internet digital marketing business[54] - The company's operating costs increased by 101.20% to ¥1,452,150,021.94 from ¥721,753,069.19, mainly due to increased sales during the reporting period[54] - The company reported a significant increase in accounts receivable, which rose by 18.00% to ¥338,867,770.39, attributed to increased sales during the reporting period[62] - The company reported a total of 1,380.26 million yuan in related party transactions during the reporting period[118] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,645,453,230.17, an increase of 9.73% from the end of the previous year[20] - The net assets attributable to shareholders amounted to CNY 729,859,337.82, which is a 9.00% increase compared to the previous year[20] - The total liabilities increased significantly, with a notable rise in financial expenses by 45.93% to ¥10,651,001.45, mainly due to increased interest expenses[58] - The total liabilities reached CNY 834.97 million, an increase of 10.9% from CNY 752.79 million at the end of 2020[162] - The company's cash and cash equivalents decreased by 286.63% to a net reduction of ¥31,616,747.42, primarily due to increased loan repayments[58] - The company's goodwill at the end of the reporting period was 180.43 million yuan, reflecting a decrease of 0.10% due to changes in the scope of consolidation[64] Cash Flow - The company reported a net cash flow from operating activities of CNY 966,233.16, a significant turnaround from a negative cash flow of CNY -82,862,327.04 in the same period last year[20] - The net cash flow from operating activities improved significantly to ¥966,233.16, compared to a negative cash flow of ¥82,862,327.04 in the previous year[58] - The net cash flow from operating activities was 19,591,945.54 CNY, a significant improvement from -47,072,236.95 CNY in the previous period[182] - Cash inflow from financing activities was 179,773,567.81 CNY, an increase from 165,000,000.00 CNY in the previous period[182] Market Position and Strategy - The company has established a leading position in the biopharmaceutical packaging sector, achieving significant sales growth in biopharmaceutical orders[33] - The company is adapting to the changing consumer market dynamics, leveraging digital marketing innovations to capture new opportunities[28] - The company is actively expanding its market presence in high-end aluminum tubes and has established stable relationships with major pharmaceutical companies, including six from the Fortune Global 500[38] - The pharmaceutical packaging market in China is expected to grow significantly due to increasing health awareness and the aging population, presenting substantial opportunities for the company[37] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[168] Research and Development - Research and development expenses increased by 72.16% to ¥25,777,866.63, primarily due to increased investment in R&D during the reporting period[58] - The company is increasing its R&D investment to keep pace with technological advancements in the packaging industry, focusing on automation and smart manufacturing[89] - The company has obtained 8 software copyrights related to blockchain technology and has built a simulated application scenario for drug traceability, which has gained significant attention from pharmaceutical manufacturers[43] Environmental and Social Responsibility - The company emphasizes its commitment to environmental protection and has implemented measures to ensure compliance with national and local environmental standards[101] - The company actively fulfills its corporate social responsibilities, especially during the COVID-19 pandemic, by prioritizing the supply of medical and essential goods packaging[102] - The company continues to focus on poverty alleviation efforts and ensures that previously impoverished individuals remain stable in their economic status[103] Corporate Governance - The company has not experienced any major litigation or arbitration matters during the reporting period[111] - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[106] - The semi-annual financial report has not been audited[108] - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[150]

Financial Performance - The company achieved operating revenue of CNY 1,625,130,768.07, representing a year-on-year increase of 91.96%[22] - The net profit attributable to shareholders reached CNY 73,749,269.45, up 78.17% compared to the same period last year[22] - The net profit after deducting non-recurring gains and losses was CNY 67,300,289.25, reflecting an increase of 80.86% year-on-year[22] - The basic earnings per share increased to CNY 0.29, a growth of 81.25% from CNY 0.16 in the previous year[22] - The company's revenue for the reporting period reached ¥1,625,130,768.07, representing a 91.96% increase compared to ¥846,595,674.22 in the same period last year, primarily driven by the growth in the internet digital marketing business[56] - The company reported a net increase in cash and cash equivalents of ¥-31,616,747.42, a decline of 286.63% from an increase of ¥16,940,715.86 in the previous period[60] - The company reported a substantial increase in investment, with a total of CNY 97.60 million in the reporting period, up 1,106.93% from CNY 8.09 million in the previous year[70] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,641,383,559.02, an increase of 9.46% from the end of the previous year[22] - The net assets attributable to shareholders amounted to CNY 725,789,666.67, up 8.39% from the previous year-end[22] - The company's total liabilities increased, primarily due to higher loan repayments, leading to a net cash flow from financing activities of ¥23,920,534.14, down 78.97% from ¥113,736,784.20[60] - The accounts receivable balance at the end of the period was ¥338,867,770.39, an increase of 18.00% from ¥287,169,493.41, attributed to increased sales[66] - Total current assets increased to ¥993,715,648.39 as of June 30, 2021, up from ¥886,093,307.99 at the end of 2020, representing a growth of approximately 12.2%[167] - Total liabilities increased to ¥834,973,166.55, compared to ¥752,787,414.95 at the end of 2020, marking an increase of approximately 10.9%[168] Cash Flow - The company reported a net cash flow from operating activities of CNY 966,233.16, a significant turnaround from a negative cash flow of CNY -82,862,327.04 in the same period last year[22] - The cash inflow from operating activities totaled CNY 1,689,957,646.20, compared to CNY 917,148,942.05 in the previous year, representing an increase of 84.2%[184] - The cash outflow from operating activities was CNY 1,688,991,413.04, up from CNY 1,000,011,269.09 in the first half of 2020, marking an increase of 68.8%[184] - The cash outflow for investing activities totaled ¥97,052,634.93, compared to ¥34,481,899.54 in the previous period[188] Market Position and Strategy - The company has established a leading position in the biopharmaceutical packaging sector, achieving significant sales growth in biopharmaceutical orders[35] - The pharmaceutical packaging market in China is expected to grow significantly due to increasing health awareness and the aging population, creating opportunities for the company[39] - The company is adapting to the evolving digital marketing landscape, driven by changes in consumer behavior and market saturation[31] - The company aims to leverage big data and new technologies to enhance its digital marketing capabilities and expand its client base[43] - The company is actively exploring new economic models in the printing and packaging industry, integrating online technologies to improve service offerings[36] Research and Development - Research and development expenses surged to ¥62,891,234.78, marking a significant increase of 320.02% compared to ¥14,973,480.48 in the previous period[60] - The company has obtained 8 software copyrights related to blockchain technology applications in drug traceability, with a primary product launched in October 2020[45] - The company has accumulated a total of 169 intellectual property rights, including 108 patents and 61 software copyrights, maintaining a leading position in the industry[49] Corporate Governance and Compliance - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[5] - There were no significant litigation or arbitration matters during the reporting period[117] - The company has not experienced any non-compliance issues regarding external guarantees[113] - The semi-annual financial report has not been audited[114] Social Responsibility and Environmental Commitment - The company emphasizes its commitment to environmental protection and has implemented measures to ensure compliance with national and local environmental standards[107] - The company actively engages in social responsibility, particularly in response to the COVID-19 pandemic, ensuring the supply of essential packaging materials[108] - The company has maintained a focus on poverty alleviation and employment support, ensuring that previously impoverished individuals remain stable[109]

Financial Performance - The company's operating revenue for Q1 2021 was ¥676,970,746.02, representing a 53.10% increase compared to ¥442,174,573.32 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was ¥30,036,045.48, up 53.11% from ¥19,617,159.88 in the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,981,142.63, reflecting a 43.54% increase from ¥18,099,941.84 year-on-year[7] - The basic earnings per share for Q1 2021 was ¥0.17, a 54.55% increase compared to ¥0.11 in the same period last year[7] - The total comprehensive income for the period was CNY 36,354,428.69, compared to CNY 24,479,212.66 in the prior year, marking a 48.6% increase[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,546,659,919.62, an increase of 3.14% from ¥1,499,501,682.56 at the end of the previous year[7] - The net assets attributable to shareholders at the end of the reporting period were ¥696,476,442.70, up 4.01% from ¥669,611,645.99 at the end of the previous year[7] - The company's total liabilities stood at CNY 777,526,659.43, up from CNY 752,787,414.95, indicating a rise in financial obligations[38] - The company's long-term equity investments increased from RMB 85.04 million to RMB 110.58 million during the same period[36] Cash Flow - The net cash flow from operating activities for Q1 2021 was -¥52,731,812.25, an improvement of 19.21% compared to -¥65,272,178.49 in the same period last year[7] - Operating cash inflow for the first quarter was CNY 92,432,700.17, an increase of 10.5% compared to CNY 83,798,671.94 in the previous period[55] - Operating cash outflow totaled CNY 96,486,471.76, down 36% from CNY 150,759,491.26 in the previous period[56] - The ending cash and cash equivalents balance was CNY 94,738,722.39, down from CNY 193,594,280.27 in the previous period[56] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,471[10] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 46.25% of the shares, totaling 83,250,000 shares[10] Research and Development - Research and development expenses surged by 311.80% to CNY 24,341,072.20, indicating a significant increase in investment in R&D activities[14] - Research and development expenses for the quarter were CNY 3,536,106.36, up from CNY 3,130,631.02, indicating a focus on innovation[48] Investments and Subsidiaries - The company completed a capital increase for its subsidiary, reducing its ownership from 70% to 49%, resulting in the subsidiary no longer being included in the consolidated financial statements[16] - The company established a wholly-owned subsidiary with a registered capital of CNY 50 million to support its strategic development and expansion plans[20] - The company signed an investment cooperation framework agreement to build an industrial park for pharmaceutical packaging and smart manufacturing in the Xi'an Xixian New Area[21] - The company signed an investment agreement to build an industrial park for green packaging and intelligent manufacturing in the Xixian New Area[22] Operational Costs - The company's gross profit margin improved, with operating costs rising by 52.38% to CNY 584,918,546.37, reflecting the increase in sales[14] - Total operating costs amounted to CNY 641,528,136.70, compared to CNY 415,316,153.16 in the prior period, reflecting a rise in operational expenses[44] Future Outlook - The company anticipates potential losses or significant changes in net profit for the first half of 2021 compared to the same period last year[27]

Financial Performance - The company's operating revenue for 2020 was CNY 1,875,342,223.97, representing a 50.35% increase compared to CNY 1,247,341,573.24 in 2019[17] - The net profit attributable to shareholders for 2020 was CNY 101,292,165.29, up 52.18% from CNY 66,562,444.36 in 2019[17] - The net profit after deducting non-recurring gains and losses was CNY 92,619,871.93, a 46.89% increase from CNY 63,052,141.42 in 2019[17] - The basic earnings per share for 2020 was CNY 0.56, reflecting a 51.35% increase from CNY 0.37 in 2019[17] - The total assets at the end of 2020 were CNY 1,499,501,682.56, an 8.80% increase from CNY 1,378,211,428.82 at the end of 2019[17] - The net assets attributable to shareholders increased by 10.71% to CNY 669,611,645.99 at the end of 2020 from CNY 604,817,969.10 at the end of 2019[17] - The company reported a negative net cash flow from operating activities of CNY -44,471,117.72 in 2020, a decline of 131.78% compared to CNY 139,913,384.06 in 2019[17] - The company achieved a total revenue of CNY 1.875 billion in 2020, representing a year-on-year growth of 50.35%[51] - The company reported a net profit of CNY 101.29 million, reflecting a year-on-year increase of 52.18%[51] Cash Flow and Investments - The company's cash and cash equivalents at the end of the period reached 296.62 million yuan, an increase of 25.51% due to increased customer payments[38] - Accounts receivable at the end of the period amounted to 287.17 million yuan, a decrease of 0.84%, which is within the normal range[38] - Inventory at the end of the period was 96.50 million yuan, reflecting a 19.60% increase, which is also within the normal range[38] - The company’s long-term equity investments reached 85.04 million yuan, an increase of 8.81% due to investment income calculated using the equity method[38] - The company achieved national high-tech enterprise certification for its internet digital marketing and supply chain segments during the reporting period[78] - The net increase in cash and cash equivalents was ¥63,103,764.43, a decrease of 21.80% year-on-year[82] - The company reported a total investment income of ¥6,389,213.86, contributing 4.45% to total profit[85] - The total investment amount for the reporting period was ¥47.56 million, a significant decrease of 71.77% compared to the previous year[91] Market Position and Growth - The company ranked 29th in the "2020 Top 100 Printing and Packaging Enterprises in China" published by "Printing Manager" [27] - The pharmaceutical packaging market in China is expected to grow at an annual rate of over 10%, with the market size increasing from 57.54 billion yuan in 2012 to 107.04 billion yuan in 2018 [28] - The company maintains stable partnerships with 8 of the world's top 500 chemical pharmaceutical companies, including Johnson & Johnson and Bayer [30] - The company is actively exploring the consumer goods market, collaborating with major clients like L'Oréal and Samsung Electronics [30] - The company aims to enhance its core competitiveness in pharmaceutical packaging through scale effects, technological reserves, and brand influence [27] - The company is focused on expanding its client base in emerging sectors such as online education and online entertainment, seeking to tap into new growth potentials[108] Research and Development - Research and development expenses increased by 29.89% to 31.48 million yuan, reflecting the company's commitment to innovation[76] - R&D investment increased by 120.35% to ¥56,021,167.75 in 2020, with R&D personnel rising by 39.69% to 183[79] - The proportion of R&D investment to operating revenue increased to 2.99%, up from 2.04% in 2019[79] - The company has received 37 new patents during the reporting period, bringing the total to 158 patents, maintaining its leading position in the industry[41] Environmental and Social Responsibility - Environmental protection investments exceeded 5 million yuan during the reporting period, with three production enterprises achieving a B-level rating in local environmental performance[44] - The company emphasizes the importance of sustainable packaging solutions in response to environmental policies, particularly the plastic restriction regulations [33] - The company is committed to creating a service platform to innovate supply chain management, aiming for rapid growth in scale and efficiency[125] - The company invested 739,900 in poverty alleviation efforts during the reporting period[195] - A total of 11 registered impoverished individuals were helped to escape poverty[196] - The company provided vocational skills training to 6 individuals, with an investment of 6,000 in training[196] Strategic Planning and Risk Management - The company emphasizes the importance of risk management and strategic planning to mitigate potential impacts on performance from external factors[137] - The company is actively monitoring national policy changes to mitigate operational risks associated with the pharmaceutical and consumer goods packaging sectors[129] - The company is addressing the challenges of rapid scale expansion by optimizing internal processes and enhancing talent acquisition and training[131] - The company acknowledges the risk of goodwill impairment due to changes in macroeconomic conditions, market demand, and industry competition, and plans to enhance post-merger management[137] Shareholder and Corporate Governance - The company plans to distribute a cash dividend of CNY 0.8 per 10 shares, with a capital reserve conversion of 4 shares for every 10 shares held[4] - The total cash dividend amount for 2020 is RMB 14.4 million, which accounts for 14.22% of the net profit attributable to shareholders[146] - The company has a history of increasing cash dividends over the past three years, with the 2020 dividend being higher than in previous years[145] - The controlling shareholder pledged to unconditionally bear any payment obligations and related costs arising from non-compliance with housing provident fund management regulations prior to the issuance of the commitment[151] - The company will ensure that it does not suffer any economic losses due to the controlling shareholder's commitments regarding social insurance compliance and related penalties[151] Digital Marketing and Technology - The digital marketing business is expected to benefit from advancements in 5G, artificial intelligence, and big data, with a focus on expanding into online education and entertainment sectors [31] - The company has established big data centers in cities like Shanghai and Beijing to support its big data integration strategy[78] - The rapid development of technologies such as AI, blockchain, and big data is creating new opportunities for digital marketing innovation[112] - The company has developed a comprehensive media resource library, covering over 1 billion users across various digital platforms, enhancing its advertising effectiveness[110] Operational Efficiency - The company is focused on maintaining its market position and exploring potential expansions in the future[175] - The company is committed to fulfilling performance commitments and will adjust strategies as necessary to achieve these goals[137] - The company is increasing investment in blockchain technology, exploring applications in the pharmaceutical industry, and enhancing its digital capabilities through "Internet+" initiatives[121]

Financial Performance - Revenue for the quarter reached ¥428,930,959.08, an increase of 8.66% compared to the same period last year[7] - Net profit attributable to shareholders was ¥24,177,493.88, representing a 48.91% increase year-over-year[7] - Basic earnings per share improved to ¥0.13, up 44.44% from the previous year[7] - The company's operating revenue increased by 51.57% to CNY 1,275,526,633.30, driven by an expanded consolidation scope and significant growth in internet advertising business[16] - Total operating revenue for Q3 2020 reached CNY 428,930,959.08, compared to CNY 394,737,866.63 in the same period last year, indicating a growth of approximately 8.6%[41] - Net profit for Q3 2020 reached CNY 30,404,623.65, representing a 49.2% increase from CNY 20,394,398.62 in Q3 2019[43] - Comprehensive income for Q3 2020 totaled CNY 30,404,623.65, compared to CNY 20,394,398.62 in Q3 2019, reflecting a growth of 49.2%[44] - Net profit for the current period was ¥81,710,268.93, representing a 47.4% increase from ¥55,451,070.50 in the previous period[50] Assets and Liabilities - Total assets increased to ¥1,468,792,904.77, up 6.57% from the previous year[7] - Net assets attributable to shareholders rose to ¥651,913,436.74, reflecting a 7.79% increase year-over-year[7] - The total amount of funds raised from the initial public offering was RMB 199,500,000, with a net amount of RMB 168,800,000 after deducting issuance costs of RMB 30,700,000[23] - The company's total liabilities amounted to CNY 736,324,063.19, compared to CNY 710,327,856.18, showing an increase of about 3.7%[35] - Long-term equity investments increased to CNY 83,734,630.74 from CNY 78,154,995.08, reflecting a growth of about 7.3%[34] - Current liabilities decreased slightly to CNY 639,714,813.19 from CNY 644,957,731.18, a reduction of about 0.5%[35] - Non-current liabilities increased to CNY 96,609,250.00 from CNY 65,370,125.00, representing a significant rise of approximately 47.8%[35] Cash Flow - Operating cash flow showed a negative net amount of ¥-28,498,351.42, a decline of 130.74% compared to the same period last year[7] - The cash inflow from operating activities amounted to CNY 1,414,790,818.85, compared to CNY 888,023,316.50 in the previous period, reflecting a significant increase[56] - The net cash flow from operating activities was negative at CNY -111,360,678.46, a decline from CNY 76,349,775.78 in the prior period[57] - The total cash inflow from financing activities was CNY 371,543,550.84, up from CNY 162,760,000.00 in the previous period, indicating strong financing support[58] - The cash outflow from investing activities was CNY 19,801,637.55, significantly lower than CNY 127,564,185.84 in the prior period, indicating reduced investment expenditures[57] Shareholder Information - The total number of shareholders at the end of the reporting period was 19,162[11] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group, holds 46.25% of the shares[11] Research and Development - Research and development expenses increased by 44.10% to CNY 23,880,225.70, reflecting higher investment in innovation[16] - Research and development expenses increased to CNY 8,906,745.22 in Q3 2020, up from CNY 6,326,092.46, reflecting a growth of 40.7%[42] Government Support - The company received government subsidies totaling ¥10,817,039.48 during the reporting period[8] - The company experienced a 171.15% increase in other income to CNY 10,817,039.48, primarily from increased government subsidies[16] Financial Adjustments - The company recorded a 73.31% increase in credit impairment losses, amounting to CNY -9,771,032.71, due to accounting policy adjustments[17] - The company reported a credit impairment loss of CNY -5,494,721.90 in Q3 2020, compared to CNY -2,091,710.93 in the previous year, indicating a significant increase in losses[42] Future Plans - The company plans to acquire 100% equity of Tianjin Global by transferring a 2.5% stake from its subsidiary, valued at CNY 2.5 million, enhancing its control over the subsidiary[18] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[50] Operational Performance - The company did not report any significant changes in its operational performance or major contracts during the reporting period[26] - There were no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[27][28] Changes in Accounting Policies - The company has implemented new revenue and leasing standards starting from 2020, which are not expected to significantly impact revenue recognition[63]